Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients

  • 53 Accesses

  • 14 Citations

Abstract

The elimination of cyclosporin A was assessed in eight pediatric renal transplant patients who received calcium channel blockers concomitantly with their immunosuppressive therapy. In three children, verapamil decreased the rate of elimination of cyclosporin A. In five children who received nifedipine, cyclosporin A elimination was also impaired, which contrasts with the reports in adult patients indicating that this calcium channel blocker has no effect on cyclosporin A elimination. When both calcium channel blockers were used on separate occasions in the same patient, nifedipine was less potent than verapamil in depressing cyclosporin A elimination. Although the number of subjects studied is small, these results likely indicate that nifedipine, as well as other calcium channel blocking drugs, must be used with caution in pediatric renal transplant patients.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Hoyer PF, Offner G, Wonigeit K, Brodehl J, Pichlmayr R (1984) Dosage of cyclosporin A in children with renal transplants. Clin Nephrol 22: 68–71

  2. 2.

    Wandstrat TL, Schroeder TJ, Myre SA (1989) Cyclosporin pharmacokinetics in pediatric transplant patients. Ther Drug Monit 11:493

  3. 3.

    Neiberger R, Weiss, R, Gomez M, Greifer I, Tellis VA, Matas AJ (1987) Elimination kinetics of cyclosporin following oral administration to children with renal transplants. Transplant Proc 19: 1525

  4. 4.

    Bryson SM (1988) Monitoring cyclosporin therapy. Pharm J 241: 42–43

  5. 5.

    Burckart G, Starzl T, Williams L, Sanghvi A, Gartner C Jr, Venkataramanan R, Zitelli B, Malatack J, Urbach A, Diven W, Ptachinski R, Shaw B, Iwatsuki S (1985) Cyclosporin monitoring and pharmacokinetics in paediatric liver transplant patients. Transplant Proc 17: 1172–1175

  6. 6.

    Yee GC, Lennon PP, Gmur DJ, Kennedy MS, Deeg HJ (1986) Agedependant cyclosporin pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40: 438–443

  7. 7.

    Ptacheinski JM, Pirson Y (1986) Cyclosporin pharmacokinetics in children following cadaveric renal transplantation. Transplant Proc 18: 776–777

  8. 8.

    Hoyer PF, Brodehl J, Ehrich JHH (1991) Practical aspects in the use of cyclosporin in paediatric nephrology, Pediatr Nephrol 5:630–638

  9. 9.

    Hoyer PF, Offner G, Oemar BS, Brodehl J, Ringe B, Pichlmayr R (1990) Four years experience with cyclosporin A in pediatric kidney transplantation. Acta Paediatr Scand 79: 622–629

  10. 10.

    Porter GA, Bennet WM, Sheldon GS (1990) Cyclosporin associated hypertension. Arch Intern Med 150: 280–283

  11. 11.

    Conley SB, Portman RJ, Lemire JM, Van Buren CT, Lewis R, Kahan BD (1988) Five years' experience with cyclosporin A and its metabolites. Transplant Proc 20 [Suppl 3]: 280–284

  12. 12.

    Kahan BD, Conley S, Portman R, Lemaire R, Wideman C, Flechner S, Van Buren C (1987) Parent-to-child transplantation with cyclosporin immunosuppression. J Pediatr 111: 1012–1016

  13. 13.

    Lindholm A, Rigden O, Lonnqvist B (1987) The role of cyclosporin dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation 43: 680–684

  14. 14.

    Joss DV, Barrett AJ, Kendra JR, Lucas CF, Desai S (1982) Hypertension and convulsions in children receiving cyclosporin A. Lancet I: 906

  15. 15.

    Ogborn MR, Crocker JFS, Belitsky P, MacDonald AS, Bitter-Seurmann H, Digout SC (1989) Cyclosporin A and hypertension in pediatric renal transplant recipients. Transplant Proc 21: 1705–1706

  16. 16.

    Schorn T, Frei U, Brackmann H, Lorenz M, Vogt P, Weise B, Pichlmayr R, Kock KM (1988) Cyclosporin-associated posttransplant hypertension. Incidence and effect on renal transplant function. Transplant Proc 20 [Suppl 3]: 610–614

  17. 17.

    Grino JM, Sabate I, Castalao AM, Alsina J (1986) Influences of diltiazem on cyclosporin clearance. Lancet I: 1387

  18. 18.

    Kohlhaw K, Wonigeit K, Frei U, Oldhafer K, Neumann K, Pichlmayr R (1988) Effect of the calcium channel blocker diltiazem on cyclosporin A blood levels and dose requirements. Transplant Proc 20 [Suppl 2]: 572–574

  19. 19.

    Pochet JM, Pirson Y (1986) Cyclosporin diltiazem interaction. Lancet I: 979

  20. 20.

    Wagner K, Henkel M, Heinemeyer G, Neumayer HH (1988) Interaction of calcium channel blockers and cyclosporin. Transplant Proc 20: 561–568

  21. 21.

    Wagner K, Neumayer HH (1985) Prevention of delayed graft function in cadaver kidney transplants by diltiazem. Lancet II: 1355–1356

  22. 22.

    Kessler M, Netter P, Renoult E, Jonon B, Mur JM, Trechot P, Dousset B (1989) Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur J Clin Pharmacol 36: 637–638

  23. 23.

    Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J (1986) Nicardipine increases cyclosporin blood levels. Lancet I: 1447

  24. 24.

    Ogborn MR, Crocker JFS, Grimm PC (1989) Nifedipine, verapamil and cyclosporin pharmacokinetics in children. Pediatr Nephrol 3: 314–316

  25. 25.

    Lindholm A, Hendricsson S (1987) Verapamil inhibits cyclosporin metabolism. Lancet I: 1262–1263

  26. 26.

    McMillan MA, Baumgarten WK, Schaefer HC, Mitchnick E, Fourtes M, Holman MJ, Tesi RJ (1987) The effects of verapamil on cellular uptake, organ distribution and pharmacology of cyclosporin. Transplant 44: 395–401

  27. 27.

    Robson RA, Graenkel M, Barratt LJ, Birkett DJ (1988) Cyclosporin-verapamil interaction. Br J Clin Pharmacol 25: 402–403

  28. 28.

    Tortorice KL, Heim-Duthoy KL, Awni WM, Venkateswara Rao K, Kasiske BL (1990) The effects of calcium channel blockers on cyclosporin and its metabolites in renal transplant patients. Ther Drug Monit 12: 321–328

  29. 29.

    Feehally J, Wall J, Mistry N (1987) Does nifedipine ameliorate cyclosporin A nephrotoxicity. BMJ 295: 310

  30. 30.

    McNally P, Mistry N, Idle J, Walls J, Feelally J (1989) Calcium channel blockers and cyclosporin metabolism. Transplanation 48: 1071

  31. 31.

    Cockburn ITR, Krupp P (1989) An appraisal of drug interactions with Sandimmune. Transplant Proc 2: 3845–3850

  32. 32.

    Whiting PH, Burke MD, Thomson AW, (1986) Drug interactions with cyclosporin: implications from animal studies. Transplant Proc 6 [Suppl 5]: 56–70

  33. 33.

    Renton KW (1985) Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 34: 2549–2553

  34. 34.

    Hendricsson S, Lindholm A (1988) Inhibition of cyclosporin metabolism by other drugs in vitro. Transplant Proc 20: 569–571

  35. 35.

    Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335: 11–15

  36. 36.

    McFadden JP, Pontin JE, Powles AV, Fry L, Idle JR (1989) Cyclosporin A decreases nifedipine metabolism. BMJ 299: 1224

  37. 37.

    De Camargo PM (1989) Cyclosporin-and nifedipine-induced gingival enlargement: an overview. J Western Soc Periodont 37: 57–64

  38. 38.

    Pedersen EB, Sorensen SS, Eiskjaer H, Skovbon H, Thomsen K (1992) Interaction between CyA and felodipine in renal transplant recipients. Kidney Int [Suppl] 36: S82-S86

  39. 39.

    Leibbrandt DM, Day RO (1992) Cyclosporin and calcium channel blockers: an exploitable drug interaction. Med J Aust 157: 296–297

Download references

Author information

Correspondence to John F. S. Crocker.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crocker, J.F.S., Renton, K.W., Le Vatte, T.L. et al. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol 8, 408–411 (1994). https://doi.org/10.1007/BF00856514

Download citation

Key words

  • Calcium channel blockers
  • Cyclosporin A
  • Interaction
  • Renal transplant patients